From cell biology to therapy: ENMD-2076 in the treatment of multiple myeloma.

Abstract

INTRODUCTION:

Multiple myeloma (MM) remains incurable, indicating the need for continued investigation of innovative strategies. Recent progress in molecular biology has advanced the discovery of novel drugs for MM. ENMD-2076 is an orally bioavailable, multi-target kinase inhibitor with multiple mechanisms of action, including anti-proliferative and pro-apoptotic activity, and anti-angiogenic effects.

AREAS COVERED:

In this review, the authors summarize the preclinical in vitro and in vivo data that have formed the rationale for clinical investigation of ENMD-2076 in MM. In addition, the authors review the early clinical results of ENMD-2076 in MM and other malignancies, and speculate on potential avenues of future clinical research in the development of this drug for MM.

EXPERT OPINION:

There is a strong preclinical rationale for investigating ENMD-2076 in MM that is confirmed by early clinical results in an ongoing Phase I trial in patients with relapsed or refractory MM. Optimal strategies for developing ENMD-2076 in MM will require better elucidation of its mechanism of action, investigation of biomarkers for response and development of rationale synergistic combinations with other active agents.

• Authors: Shuhong Zhang, Sherif S Farag
• Journal: Expert opinion on investigational drugs (Expert Opin Investig Drugs) Vol. 20 Issue 7 Pg. 1015-28 (Jul 2011) ISSN: 1744-7658 [Electronic] England
• PMID: 21615212 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)

Chemical References

• Antineoplastic Agents
• ENMD 2076
• Pyrazoles
• Pyrimidines

Topics

• Animals
• Antineoplastic Agents (metabolism, therapeutic use)
• Clinical Trials as Topic (methods)
• Humans
• Multiple Myeloma (drug therapy, metabolism)
• Pyrazoles (metabolism, therapeutic use)
• Pyrimidines (metabolism, therapeutic use)
• Signal Transduction (drug effects, physiology)
• Treatment Outcome